"大阪梅田駅近くの内科AMC西梅田クリニックです。私たちは病気を治すだけでなく、なるべく病気にならないように、また病気にかかっても重くならないようにするための取り組みを行っていきたいと考えます。 そのために重要なことは、定期的な健康診断、そしてそれに基づく健康管理と適切な助言を提供することです。また、それらを気軽に利用していただけるような環境づくりも重要です。 AMC西梅田クリニックは、JR大阪駅、梅田駅、福島駅、北新地駅、阪急、阪神、地下鉄の各ターミナル駅の徒歩圏に位置することで、特に大阪を中心に働く方々に受診の利便性を確保できるかと考えます。 ビジネスマン、ビジネスウーマンの真の健康を守り、かつ増進するために、次の三つのミッションを我々自身に課したいと思います。"

During the past decade, AMC Nishiumeda Clinic conducted 19 clinical trials. In the 10-year time frame, 19 clinical trials started and 6 clinical trials were completed, i.e. on average, 31.6% percent of trials that started reached the finish line to date. In the past 5 years, 15 clinical trials started and 3 clinical trials were completed. i.e. 20% of trials that started reached the finish line.

Out of the total clinical trials conducted in "AMC Nishiumeda Clinic" #1 sponsor was "Eli Lilly and Company" with 12 trials, followed by "Boehringer Ingelheim" with 3 trials sponsored, "Amgen" with 1 trials sponsored, "Bayer" with 1 trials sponsored and "Kowa Company, Ltd." with 1 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "AMC Nishiumeda Clinic" #1 collaborator was "Eli Lilly and Company" with 3 trials as a collaborator, "Medical Research Council Population Health Research Unit, CTSU, University of Oxford (academic lead)" with 1 trials as a collaborator and "Takeda" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "AMC Nishiumeda Clinic" are "Obesity" (5 trials), "Diabetes Mellitus, Type 2" (3 trials), "Overweight" (3 trials), "Type 2 Diabetes" (3 trials) and "Chronic Kidney Disease" (2 trials). Many other conditions were trialed in "AMC Nishiumeda Clinic" in a lesser frequency.

Most popular intervention types in "AMC Nishiumeda Clinic" are "Drug" (20 trials), "Other" (2 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (13 trials), "Tirzepatide" (7 trials), "Dulaglutide" (3 trials), "Empagliflozin" (3 trials) and "Alpha-Glucosidase Inhibitors (α-GI)" (1 trials). Other intervention names were less common.

The vast majority of trials in "AMC Nishiumeda Clinic" are 21 trials for "All" genders.

Currently, there are NaN active trials in "AMC Nishiumeda Clinic". undefined are not yet recruiting, 5 are recruiting, 9 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 7 completed trials in AMC Nishiumeda Clinic, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in AMC Nishiumeda Clinic, 0 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 14 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".